{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:47:31Z","timestamp":1792057651582,"version":"4.4.0"},"reference-count":52,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Given the effectiveness of pre-exposure prophylaxis (PrEP), the HIV prevention landscape is expanding rapidly \u2013 including recently approved injectable options which have shown high efficacy in clinical trials. As head-to-head trials of injectable PrEPs are not feasible, indirect treatment comparisons (ITCs) are of value to generate comparative estimates of efficacy and safety. However, several methodological challenges must be carefully considered when conducting these ITCs. This review outlines these complexities to support informed decision-making.\n                    <jats:bold>Main text:<\/jats:bold>\n                    We identified methodological considerations through a narrative review of available literature (including leveraging published systematic reviews), evidence from PrEP trials and, where applicable, reference to methodological guidelines. Our review suggests treatment effect modifiers (TEMs) for PrEP are poorly defined in the HIV PrEP literature and, due to the high efficacy of injectable compared with oral PrEP, encompass potential prognostic factors (such as background HIV incidence). Challenges in comparing potential TEMs across trials were also noted due to, for example, differences in measurement methodology and reporting timepoint for adherence. Accounting for variation in follow-up across studies within potential ITCs is critical as HIV acquisition is a rare, time-dependent event. Additionally, zero or few events occur within injectable PrEP trials in HIV, challenging variance estimation and necessitating alternative statistical approaches. Population-adjustment methods are similarly complicated.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This review outlines key considerations and offers practical recommendations to inform robust conduct of ITCs of PrEP, and support the interpretation of results. Areas of further research to strengthen future comparative evidence are also highlighted.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0103","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:14:18Z","timestamp":1792055658000},"source":"Crossref","is-referenced-by-count":0,"title":["Methodological considerations for indirect treatment comparisons of HIV incidence for long-acting injectable pre-exposure prophylaxis"],"prefix":"10.57264","author":[{"given":"Tristan","family":"Curteis","sequence":"first","affiliation":[{"name":"Costello Medical Consulting, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan N","family":"Franklin","sequence":"additional","affiliation":[{"name":"Costello Medical Consulting, Boston, MA 02108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca K","family":"Judge","sequence":"additional","affiliation":[{"name":"Costello Medical Consulting, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3890-8000","authenticated-orcid":false,"given":"Anna","family":"Zolotor","sequence":"additional","affiliation":[{"name":"University of North Carolina Gillings School of Global Public Health Department of Epidemiology, Chapel Hill, NC 27599-7435, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-8581","authenticated-orcid":false,"given":"James","family":"Jarrett","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-8011","authenticated-orcid":false,"given":"Christoph C","family":"Carter","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Mezzio","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"e_1_3_6_3_2","unstructured":"UNAIDS. Global HIV Statistics Fact Sheet 2025. (Accessed 26 January 2026). https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"e_1_3_6_4_2","unstructured":"Yale Medicine. Human immunodeficiency virus (HIV) fact sheet. (Accessed 26 January 2026). https:\/\/www.yalemedicine.org\/conditions\/human-immunodeficiency-virus-hiv"},{"key":"e_1_3_6_5_2","unstructured":"World Health Organization. Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. (2025)."},{"key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"e048478","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","author":"Murchu EO","year":"2022","unstructured":"Murchu EO, Marshall L, Teljeur C Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open 12, e048478 (2022).","journal-title":"BMJ Open"},{"key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"ofae569","DOI":"10.1093\/ofid\/ofae569","article-title":"Trajectories of adherence to oral pre-exposure prophylaxis and risks of HIV and sexually transmitted infections","volume":"11","author":"Unigwe IF","year":"2024","unstructured":"Unigwe IF, Goodin A, Lo-Ciganic WH Trajectories of adherence to oral pre-exposure prophylaxis and risks of HIV and sexually transmitted infections. Open Forum Infect. Dis. 11, ofae569 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/infdis\/jiad550","article-title":"Assessing per-sex-act HIV-1 risk reduction among women using the dapivirine vaginal ring","volume":"229","author":"Stalter RM","year":"2024","unstructured":"Stalter RM, Dong TQ, Hendrix CW Assessing per-sex-act HIV-1 risk reduction among women using the dapivirine vaginal ring. J. Infect. Dis. 229, 1158\u20131165 (2024).","journal-title":"J. Infect. Dis."},{"key":"e_1_3_6_9_2","unstructured":"Gilead Sciences. Yeztugo\u00ae (Lenacapavir) is now the first and only FDA-approved HIV prevention option offering 6 months of protection. (2025). (Accessed 26 January 2026). https:\/\/www.gilead.com\/news\/news-details\/2025\/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection"},{"key":"e_1_3_6_10_2","unstructured":"US Food and Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention. drug given every two months rather than daily pill is important tool in effort to end the HIV epidemic. (2021). (Accessed 26 January 2026). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention"},{"key":"e_1_3_6_11_2","unstructured":"Gilead Sciences. European commission authorizes twice-yearly Yeytuo\u00ae (Lenacapavir) for HIV prevention. (2025). (Accessed 26 January 2026). https:\/\/www.gilead.com\/news\/news-details\/2025\/european-commission-authorizes-twice-yearly-yeytuo-lenacapavir-for-hiv-prevention"},{"key":"e_1_3_6_12_2","unstructured":"ViiV Healthcare. European Commission authorises ViiV Healthcare's Apretude (cabotegravir long-acting and tablets) for HIV prevention. (2023). (Accessed 26 January 2026). https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2023\/september\/european-commission-authorises-viiv-healthcare\/"},{"key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker L-G","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N. Engl. J. Med. 391, 1179\u20131192 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley CF","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N. Engl. J. Med. 392(13), 1261\u20131276 (2025).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz RJ","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a Phase III, randomised clinical trial","volume":"399","author":"Delany-Moretlwe S","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a Phase III, randomised clinical trial. Lancet 399, 1779\u20131789 (2022).","journal-title":"Lancet"},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/COH.0000000000000901","article-title":"Future options for long-acting HIV treatment and prevention","volume":"20","author":"Arens Y","year":"2025","unstructured":"Arens Y, Gulick RM. Future options for long-acting HIV treatment and prevention. Curr. Opin. HIV AIDS 20, 39\u201347 (2025).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cpdd.1538","article-title":"A randomized Phase 1 study evaluating pharmacokinetics, safety, and tolerability of a high-concentration, long-acting cabotegravir formulation in adults without HIV","volume":"14","author":"Han K","year":"2025","unstructured":"Han K, Benn P, Sievers J A randomized Phase 1 study evaluating pharmacokinetics, safety, and tolerability of a high-concentration, long-acting cabotegravir formulation in adults without HIV. Clin. Pharmacol. Drug Dev. 14, 528\u2013541 (2025).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"e_1_3_6_19_2","unstructured":"ClinicalTrials.gov. Study of lenacapavir as a once-yearly injection for HIV pre-exposure prophylaxis (PrEP) (PURPOSE 365): Gilead Sciences (Responsible Party) 2025: NCT07047716. (Accessed 26 January 2026). https:\/\/clinicaltrials.gov\/study\/NCT07047716"},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"e076843","DOI":"10.1136\/bmjopen-2023-076843","article-title":"Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07\u2013523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, Phase 2 CAPRISA 012C trial","volume":"13","author":"Mahomed S","year":"2023","unstructured":"Mahomed S, Garrett N, Potloane D Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07\u2013523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, Phase 2 CAPRISA 012C trial. BMJ Open 13, e076843 (2023).","journal-title":"BMJ Open"},{"key":"e_1_3_6_21_2","unstructured":"Merck & Co. Inc. Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill. In collaboration with the Gates Foundation Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally. (2025). (Accessed 26 January 2026). https:\/\/www.merck.com\/news\/merck-to-initiate-phase-3-trials-for-investigational-once-monthly-hiv-prevention-pill\/"},{"key":"e_1_3_6_22_2","unstructured":"AVAC. The future of ARV-based prevention and more: AIDS vaccine advocacy coalition. (2024). (Accessed 26 January 2026). https:\/\/avac.org\/wp-content\/uploads\/2024\/07\/FutureARVbasedPrevention_Oct2024.pdf"},{"key":"e_1_3_6_23_2","unstructured":"National Institute for Health and Care Excellence (NICE). Single technology appraisal and highly specialised technologies evaluation: user guide for company evidence submission template. (2024). (Accessed 26 January 2026). https:\/\/www.nice.org.uk\/process\/pmg24"},{"key":"e_1_3_6_24_2","unstructured":"Member State Coordination Group on Health Technology Assessment. Guidance on filling the joint clinical assessment (JCA) dossier template \u2013 Medicinal products. (2024). (Accessed 26 January 2026). https:\/\/health.ec.europa.eu\/publications\/guidance-filling-joint-clinical-assessment-jca-dossier-template-medicinal-products_en"},{"key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s40121-025-01172-9","article-title":"Indirect treatment comparison of long-acting injectable cabotegravir as pre-exposure prophylaxis when compared with no pre-exposure prophylaxis for HIV prevention","volume":"14","author":"Hawkins N","year":"2025","unstructured":"Hawkins N, O'Brien P, Thompson J Indirect treatment comparison of long-acting injectable cabotegravir as pre-exposure prophylaxis when compared with no pre-exposure prophylaxis for HIV prevention. Infect. Dis. Ther. 14, 1739\u20131753 (2025).","journal-title":"Infect. Dis. Ther."},{"key":"e_1_3_6_26_2","volume-title":"Indirect Treatment Comparison of the Efficacy of Cabotegravir and Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) Versus No PrEP and Oral Tenofovir Disoproxil Fumarate\/Emtricitabine (TDF\/FTC)","author":"Hawkins N","year":"2025","unstructured":"Hawkins N, Thompson J, Grove R Indirect Treatment Comparison of the Efficacy of Cabotegravir and Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) Versus No PrEP and Oral Tenofovir Disoproxil Fumarate\/Emtricitabine (TDF\/FTC). International AIDS Society Meeting, Kigali, Rwanda (2025)."},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1007\/s12325-026-03591-7","article-title":"Indirect treatment comparison of the efficacy of long-acting injectable cabotegravir compared with lenacapavir for HIV pre-exposure prophylaxis","volume":"43","author":"Hawkins N","year":"2026","unstructured":"Hawkins N, Hazra A, Brizzi M Indirect treatment comparison of the efficacy of long-acting injectable cabotegravir compared with lenacapavir for HIV pre-exposure prophylaxis. Adv. Ther. 43, 3535\u20133551 (2026).","journal-title":"Adv. Ther."},{"key":"e_1_3_6_28_2","unstructured":"Higgins J Thomas J Chandler J Cochrane Handbook for Systematic Reviews of Interventions. version 6.5 (updated August 2024) Cochrane. (2024). (Accessed 26 January 2026). http:\/\/www.cochrane.org\/handbook"},{"key":"e_1_3_6_29_2","unstructured":"Dias S Welton NJ Sutton AJ NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. (2011)."},{"key":"e_1_3_6_30_2","unstructured":"Akello D. Adherence levels and associated factors to pre-exposure prophylaxis among high risk individuals enrolled at public health facilities in Mbale district. Makerere University Institutional Repository 2019. (Accessed 18 February 2026). https:\/\/makir.mak.ac.ug\/items\/3f48c3d0-d382-48c4-ab79-cae88e30cf6e"},{"key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"1263422","DOI":"10.3389\/frph.2023.1263422","article-title":"Adherence to daily, oral TDF\/FTC PrEP during periconception among HIV-exposed South African women","volume":"5","author":"Hurwitz KE","year":"2023","unstructured":"Hurwitz KE, Isehunwa OO, Hendrickson KR Adherence to daily, oral TDF\/FTC PrEP during periconception among HIV-exposed South African women. Front. Reprod. Health 5, 1263422 (2023).","journal-title":"Front. Reprod. Health"},{"key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/S2352-3018(19)30433-3","article-title":"Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study","volume":"7","author":"Koss CA","year":"2020","unstructured":"Koss CA, Charlebois ED, Ayieko J Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. Lancet HIV 7, e249\u2013e261 (2020).","journal-title":"Lancet HIV"},{"key":"e_1_3_6_33_2","volume-title":"Real-World Adherence of HIV-1 Oral Pre-Exposure Prophylaxis Regimens in the USA: A Group-Based Trajectory Modeling Approach","author":"Tao L","year":"2024","unstructured":"Tao L, Yang J, Shannon B Real-World Adherence of HIV-1 Oral Pre-Exposure Prophylaxis Regimens in the USA: A Group-Based Trajectory Modeling Approach. 5th International AIDS Conference, Munich, Germany (2024)."},{"key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher HC","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50, 683\u2013691 (1997).","journal-title":"J. Clin. Epidemiol."},{"key":"e_1_3_6_35_2","unstructured":"Phillippo DM Ades AE Dias S NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (2016)."},{"key":"e_1_3_6_36_2","unstructured":"Member State Coordination Group on Health Technology Assessment. Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. (2024). (Accessed 26 January 2026). https:\/\/health.ec.europa.eu\/publications\/methodological-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons_en"},{"key":"e_1_3_6_37_2","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Process and methods. (2013) (Accessed: 26 January 2026). http:\/\/www.nice.org.uk\/process\/pmg9"},{"key":"e_1_3_6_38_2","doi-asserted-by":"crossref","first-page":"e1001511","DOI":"10.1371\/journal.pmed.1001511","article-title":"Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa","volume":"10","author":"Haberer JE","year":"2013","unstructured":"Haberer JE, Baeten JM, Campbell J Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 10, e1001511 (2013).","journal-title":"PLoS Med."},{"key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1038\/s41591-023-02564-5","article-title":"Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence","volume":"29","author":"Moore M","year":"2023","unstructured":"Moore M, Stansfield S, Donnell DJ Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence. Nat. Med. 29, 2748\u20132752 (2023).","journal-title":"Nat. Med."},{"key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1093\/ofid\/ofab466.1061","article-title":"866. Adherence to F\/TDF for PrEP in dried blood spots and HIV infection rates: a pooled analysis of global PrEP studies","volume":"8","author":"Liu A","year":"2021","unstructured":"Liu A, Liu A, Grant R 866. Adherence to F\/TDF for PrEP in dried blood spots and HIV infection rates: a pooled analysis of global PrEP studies. Open Forum Infect. Dis. 8, S524\u2013S525 (2021).","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"e_1_3_6_41_2","doi-asserted-by":"crossref","first-page":"e01710","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"Anderson PL","year":"2018","unstructured":"Anderson PL, Liu AY, Castillo-Mancilla JR Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob. Agents Chemother. 62(1), e01710\u2013e01717 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1007\/s10461-025-04741-8","article-title":"Performance of adherence measures for oral, tenofovir-based HIV pre-exposure prophylaxis: a systematic review","volume":"29","author":"Zeballos D","year":"2025","unstructured":"Zeballos D, Guimar\u00e3es NS, Pereira M Performance of adherence measures for oral, tenofovir-based HIV pre-exposure prophylaxis: a systematic review. AIDS Behav. 29(9), 2841\u20132854 (2025).","journal-title":"AIDS Behav."},{"issue":"8","key":"e_1_3_6_43_2","doi-asserted-by":"crossref","first-page":"ofac405","DOI":"10.1093\/ofid\/ofac405","article-title":"Tenofovir-diphosphate in dried blood spots vs tenofovir in urine\/plasma for oral preexposure prophylaxis adherence monitoring","volume":"9","author":"Niu X","year":"2022","unstructured":"Niu X, Kubiak RW, Siriprakaisil O Tenofovir-diphosphate in dried blood spots vs tenofovir in urine\/plasma for oral preexposure prophylaxis adherence monitoring. Open Forum Infect. Dis. 9(8), ofac405 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"e_1_3_6_44_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, Phase 3 trial","volume":"14","author":"Baeten JM","year":"2014","unstructured":"Baeten JM, Donnell D, Mugo NR Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, Phase 3 trial. Lancet Infect. Dis. 14, 1055\u20131064 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_6_45_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten JM","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399\u2013410 (2012).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_46_2","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled Phase 3 trial","volume":"381","author":"Choopanya K","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 381, 2083\u20132090 (2013).","journal-title":"Lancet"},{"key":"e_1_3_6_47_2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant RM","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587\u20132599 (2010).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_48_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo JM","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509\u2013518 (2015).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_49_2","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina J-M","year":"2015","unstructured":"Molina J-M, Capitant C, Spire B On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373, 2237\u20132246 (2015).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_50_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme L","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411\u2013422 (2012).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_51_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack S","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387, 53\u201360 (2016).","journal-title":"Lancet"},{"key":"e_1_3_6_52_2","volume-title":"Modern epidemiology","author":"Rothman KJ","year":"2008","unstructured":"Rothman KJ, Greenland S, Lash T. Modern epidemiology. (3rd Edition). (2008).","edition":"3"},{"key":"e_1_3_6_53_2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting MJ","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 23, 1351\u20131375 (2004).","journal-title":"Stat. Med."},{"key":"e_1_3_6_54_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jclinepi.2008.08.005","article-title":"Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials","volume":"62","author":"Tsang R","year":"2009","unstructured":"Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J. Clin. Epidemiol. 62, 609\u2013616 (2009).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:14:26Z","timestamp":1792055666000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":52,"alternative-id":["10.57264\/cer-2026-0103"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0103","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"e260103"}}